The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Somatostatin Analogs in Acromegaly
Abstract
Since their introduction into clinical practice, somatostatin analogs have been the medical therapy of choice for the treatment of acromegaly. Therefore, considerable data exist on their use for this purpose. This review summarizes the literature on somatostatin analog therapy of acromegaly and describes its efficacy in terms of the main goals for the treatment of acromegaly, i.e. normalization of hormone levels, GH and IGF-I, relief of the signs and symptoms of acromegaly, and pituitary tumor shrinkage. The side effects of somatostatin analogs and their role as primary therapy for acromegaly are also discussed. The review focuses on the data with the depot analogs because these formulations are most likely to be chosen in clinical practice. The native peptide somatostatin is widely distributed in the central nervous system and peripheral tissues (1–3). Somatostatin is processed from its precursor into its two biologically active forms, somatostatin-14 and somatostatin-28 (2). Native somatostatin has diverse physiological actions, including its role as a central nervous system neurotransmitter and neuromodulator, regulatory hormone in the gastrointestinal tract and pancreas, and inhibitor of GH and TSH release in the pituitary (2, 3). In vitro, native somatostatin retains its inhibitory effect on GH secretion in many GH-secreting tumors, and this led to the development of analogs of somatostatin for clinical use in the treatment of acromegaly (4). The two analogs of somatostatin available for clinical use are the cyclic octapeptides octreotide (Dphe-cys-phe-Dtrp-lys-thr-cys-thr-ol) and lanreotide (Dnal-cys-tyr-Dtrp-lys-val-cys-thr) (1, 5–7). Octreotide is the only analog currently available for clinical use in the treatment of acromegaly in the United States. Lanreotide has been used extensively in Europe for the treatment of acromegaly. Certain properties of these analogs, including their greater potency for GH suppression and longer half-life after peripheral administration than somatostatin, make them advantageous to the native hormone for the treatment of acromegaly. For example, octreotide is 45 times more potent at suppressing pituitary GH secretion than native somatostatin-14 (8) and has a half-life of 2 h when given sc (9). Somatostatin analogs and native somatostatin elicit their biological effects by activating somatostatin receptors. There are five distinct somatostatin receptors, types 1–5 (10). They are all G protein-coupled receptors, but differ in their regulatory/signaling pathways, tissue distribution, and the affinity to which the somatostatin analogs bind to them (6, 10). Relative to native somatostatin, the analogs have a narrowed spectrum of receptor activity that allows for greater specificity of GH suppression. Octreotide and lanreotide have greatest affinity for receptor subtypes 2 and 5, with their affinity for subtype 2 being about 10-fold higher than for subtype 5 (1). Receptor subtypes 2 and 5 are those through which endogenous somatostatin suppression of GH occurs (11) and are also the predominant types of somatostatin receptors found in GH-secreting pituitary tumors (12–15). A significant percentage of GH-secreting pituitary tumors are resistant to octreotide and lanreotide, and this may be explained in part by variable tumoral expression or reduced receptor density of subtypes 2 or 5 on the tumors of these patients (16). The first preparation of somatostatin analog available for clinical use was sc-administered octreotide. After sc injection, serum octreotide levels rise within 30 min and then fall over the next few hours. The maximal suppressive effect of octreotide on GH levels occurs between 2 and 6 h after the injection (17). GH levels rise between injections given every 8 h, but with continued treatment this rise is lessened (9). Importantly also, in somatostatin analog responsive patients, the suppressive effect on GH secretion does not wane with time. The typical dose of octreotide in its sc form is 100–250 μg thrice daily, but doses up to 1500 μg over a 24-h period can be given (18). Octreotide is also available in a long-acting release (LAR) preparation, octreotide LAR, in which octreotide is enclosed in microspheres of a slowly biodegrading polymer that allows for prolonged release of drug (19). After the injection of octreotide LAR, octreotide levels rise briefly, corresponding to release of octreotide from the surface of the microspheres. Octreotide levels then fall and begin to rise again about 7–14 d later after the injection and remain elevated for an average of 34 d (20). Steady-state conditions are usually achieved after two to three injections. GH levels fall and rise in response to the changing octreotide levels (20, 21). The usual starting dose of octreotide LAR is 20 mg with titration down to 10 mg or up to 30 or 40 mg, based on the response of GH and IGF-I levels. The manufacturer recommends monthly drug administration, allowing for an overlap of injectio
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. J., & Pless, J. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90087-x · Cited by 1,331
Criteria for Cure of Acromegaly: A Consensus Statement
Giustina, A. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.526 · Cited by 987
Molecular Biology of Somatostatin Receptors*
REISINE, T., & BELL, G. I. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-4-427 · Cited by 618
Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly1
Swearingen, B., Barker, F. G., Katznelson, L., Biller, B. M. K., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P. M., & Zervas, N. T. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.10.5222 · Cited by 586
Reichlin, S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312223092506 · Cited by 577
Determinants of clinical outcome and survival in acromegaly
Rajasoorya, C., Holdaway, I. M., Wrightson, P., Scott, D. J., & Ibbertson, H. K. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03789.x · Cited by 565
Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls
Breier, B. H., Gallaher, B. W., & Gluckman, P. D. (1991) · Journal of Endocrinology · doi:10.1677/joe.0.1280347 · Cited by 415
Freda, P. U., Wardlaw, S. L., & Post, K. D. (1998) · Journal of Neurosurgery · doi:10.3171/jns.1998.89.3.0353 · Cited by 281
Self-citationLAMBERTS, S. W. J. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-4-417 · Cited by 265
Shimon, I., Yan, X., Taylor, J. E., Weiss, M. H., Culler, M. D., & Melmed, S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119779 · Cited by 260
Long-term Treatment of 189 Acromegalic Patients With the Somatostatin Analog Octreotide
Vance, M. L. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400080073013 · Cited by 237
Effect of Octreotide Pretreatment on Surgical Outcome in Acromegaly
Colao, A., Ferone, D., Cappabianca, P., De, M. D. B., Marzullo, P., Monticelli, A., Alfieri, A., Merola, B., Calì, A., de Divitiis, E., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.10.3308 · Cited by 234
Somatostatin receptor subtype gene expression in pituitary adenomas
Miller, G. M. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.4.1386 · Cited by 220
Freda, P. U., Post, K. D., Powell, J. S., & Wardlaw, S. L. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.11.5266 · Cited by 201
Self-citationGreenman, Y. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.79.3.724 · Cited by 190
Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors
Panetta, R., & Patel, Y. C. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00956-2 · Cited by 185
Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors
Greenman, Y. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.2.398 · Cited by 180
Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release Lanreotide1
Caron, P. J., Morange, I., Cogne, M., & Jaquet, P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3714 · Cited by 179
Saveanu, A., Gunz, G., Dufour, H., Caron, P., Fina, F., Ouafik, L., Culler, M. D., Moreau, J. P., Enjalbert, A., & Jaquet, P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7099 · Cited by 168
Results of a European Multicentre Study with Sandostatin® LAR® in Acromegalic Patients
Lancranjan, I., Atkinson, A. B., & Sandostatin® LAR® Group# (1999) · Pituitary · doi:10.1023/a:1009980404404 · Cited by 166
Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly
Stewart, P. M., Kane, K. F., Stewart, S. E., Lancranjan, I., & Sheppard, M. C. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.11.3267 · Cited by 161
Prediction of efficacy of octreotide therapy in patients with acromegaly
Colao, A. A. L., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Sarno, A. D., Longobardi, S., Merola, B., Salvatore, M., & Lombardi, G. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.6.2356 · Cited by 147
Presurgical octreotide treatment in acromegaly
Stevenaert, A., Harris, A. G., Kovács, K., et al. (1992) · Metabolism · doi:10.1016/0026-0495(92)90031-5 · Cited by 147
Sandostatin® LAR®: A promising therapeutic tool in the management of acromegalic patients
Lancranjan, I., Bruns, C., Grass, P. N., Jaquet, P., Jervell, J., Kendall-Taylor, P., Lamberts, S. W. J., Marbach, P., Ørskov, H., Pagani, G. A., et al. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90087-6 · Cited by 145
Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR®) for the management of acromegaly
Davies, P. H. O., Stewart, S. E., Lancranjan, I., Sheppard, M. C., & Stewart, P. M. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00389.x · Cited by 137
SASSOLAS, G., Harris, A. G., James-Deidier, A., & THE FRENCH SMS 201–995≌ACROMEGALY STUDY GROUP† (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-2-391 · Cited by 136
Effect of Octreotide, a Somatostatin Analog, on Sleep Apnea in Patients with Acromegaly
Grunstein, R. R., Ho, K. K. Y., & Sullivan, C. E. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-7-199410010-00002 · Cited by 134
Therapeutic Efficacy of the Somatostatin Analog SMS 201-995 (Octreotide) in Acromegaly
Ho, K., Weissberger, A. J., Marbach, P., & Lazarus, L. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-3-173 · Cited by 133
The impact of obesity on hormonal parameters in hirsute and nonhirsute women
Bernasconi, D., Monte, P. D., Meozzi, M., Randazzo, M., Marugo, A., Badaracco, B., & Marugo, M. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90202-4 · Cited by 109
Giustina, A., Boni, E., Romanelli, G., Grossi, V., & Giustina, G. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80721-8 · Cited by 94
A comparison of lanreotide and octreotide LAR for treatment of acromegaly
Turner, Vadivale, Keenan, & Wass (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00853.x · Cited by 85
Somatostatin receptors present knowledge and future directions
Schönbrunn, A. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_2.s17 · Cited by 72
The effect of a new slow‐release, long‐acting somatostatin analogue, lanreotide, in acromegaly
Al‐Maskari, M., Gebbie, J., & Kendall-Taylor, P. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.8270836.x · Cited by 55
Stewart, P. M., Stewart, S. E., Clark, P. M. S., & Sheppard, M. C. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00660.x · Cited by 42
Tulipano, G., Bonfanti, C., Milani, G., Billeci, B., Bollati, A., Cozzi, R. C., Maira, G., Murphy, W. A., Poiesi, C., Turazzi, S., et al. (2001) · Neuroendocrinology · doi:10.1159/000054651 · Cited by 39
Long-Acting Octreotide LAR Compared with Lanreotide SR in the Treatment of Acromegaly
Kendall‐Taylor, P., Miller, M. A., Gebbie, J., Turner, S., & Al-Maskari, M. Y. (2000) · Pituitary · doi:10.1023/a:1009997506216 · Cited by 35
Razzore, P., Colao, A. A. L., Baldelli, R., Gaia, D., Marzullo, P., Ferretti, E., Ferone, D., Jaffrain‐Rea, M., Tamburrano, G., Lombardi, G., et al. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00812.x · Cited by 22
Cited by
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Reubi, J. C. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0007 · Cited by 1,131
Advances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
Acromegaly pathogenesis and treatment
Melmed, S. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39375 · Cited by 687
Opportunities in somatostatin research: biological, chemical and therapeutic aspects
Weckbecker, G., Lewis, I., Albert, R., Schmid, H. A., Hoyer, D., & Bruns, C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1255 · Cited by 559
Protein Modification, Bioconjugation, and Disulfide Bridging Using Bromomaleimides
Smith, M. E. B., Schumacher, F. F., Ryan, C. P., Tedaldi, L. M., Papaioannou, D., Waksman, G., Caddick, S., & Baker, J. R. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908610s · Cited by 377
Metadata
- Authors
- Freda, P. U.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-07-01
- Volume
- 87
- Issue
- 7
- Pages
- 3013-3018
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W1976977515
- Cited by
- 298
- References
- 37
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.